The Effects of Real-World Evidence on the Treatment of HER2+ mBC - Episode 6
Adverse Events Seen With Second- and Third-Line Therapies in Patients With HER2+ mBC
Jane Meisel, MD, discusses managing adverse events in patients receiving second- or third-line treatments for HER2+ metastatic breast cancer, emphasizing close monitoring, patient communication, and symptom-specific interventions.
Related Content:
